<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741906</url>
  </required_header>
  <id_info>
    <org_study_id>Oral rehabilitation of MRONJ</org_study_id>
    <nct_id>NCT04741906</nct_id>
  </id_info>
  <brief_title>Dental Rehabilitation of Cancer Patients With Bone Metastases on High Dose Antiresorptives</brief_title>
  <official_title>Dental Rehabilitation of Cancer Patients With Bone Metastases on High Dose Antiresorptives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanne Werner Moeller Andersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Straumann AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to examine the feasibility of dental implant insertion in a pilot project&#xD;
      in patients on high dose antiresorptive treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project includes 30 patients with bone metastases on high dose antiresorptive treatment&#xD;
      (HDAR) for the prevention of bone complications. Definition of HDAR refers to the&#xD;
      antiresorptive dose used per label in cancer patients with bone metastases to prevent bone&#xD;
      complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Dental implant survival</measure>
    <time_frame>3 months</time_frame>
    <description>Defined as presence of the implant in the jaw after initial implant surgery before abutment surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dental implant survival</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as presence of the implant at time of final prosthetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dental implant survival</measure>
    <time_frame>18 months</time_frame>
    <description>Defined as presence of the implant 1 year after loading of the final prosthetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dental implant survival</measure>
    <time_frame>30 months</time_frame>
    <description>Defined as presence of the implant 2 years after loading of the final prosthetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dental Implant success</measure>
    <time_frame>30 months</time_frame>
    <description>Defined as less marginal bone loss than 1.5 mm the first year, and 0.2 mm per year thereafter at time of assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of medical related osteonecrosis of the jaw (MRONJ)</measure>
    <time_frame>30 months</time_frame>
    <description>Defined as no exposed bone, no fistula, no radiologic sign of MRONJ</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral Health Impact Profile</measure>
    <time_frame>30 months</time_frame>
    <description>Using OHIP-49 questionnaire to evaluate oral health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-H&amp;N 35</measure>
    <time_frame>30 months</time_frame>
    <description>Performance of the EORTC questionnaire for the assessment of quality of life in head and neck cancer patients</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Missing Teeth</condition>
  <condition>Implants</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Previous tooth extraction</arm_group_label>
    <description>Cancer patients (breast, prostate or multiple myeloma) with bone metastases on high dose antiresorptive treatment who have had previous tooth extraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previous resection</arm_group_label>
    <description>Cancer patients (breast, prostate or multiple myeloma) with bone metastases on high dose antiresorptive treatment who have lost teeth due to having previous osteonecrosis of the jaw which has been successfully surgically treated and healed for at least 3 months without recurrence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simultaneously with resection</arm_group_label>
    <description>Cancer patients (breast, prostate or multiple myeloma) with ongoing osteonecrosis of the jaw to be surgically treated with block resection of the lower jaw and insertion of a titanium reconstruction plate. Simultaneous insertion of dental implants, or resection of the upper jaw where there is sufficient remaining bone volume to have implants inserted simultaneously (without bone augmentation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dental implant surgery</intervention_name>
    <description>Dental surgery in cancer patients in high dose antiresorptive treatment</description>
    <arm_group_label>Previous resection</arm_group_label>
    <arm_group_label>Previous tooth extraction</arm_group_label>
    <arm_group_label>Simultaneously with resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prosthetic treatment</intervention_name>
    <description>Prosthetic treatment and loading of the dental implants</description>
    <arm_group_label>Previous resection</arm_group_label>
    <arm_group_label>Previous tooth extraction</arm_group_label>
    <arm_group_label>Simultaneously with resection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Total or partial toothless cancer patients, treated at Copenhagen University Hospital due&#xD;
        to treatment with high dose antiresorptive treatment. The patients had former tooth&#xD;
        extractions or resections of the jaw at our clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cancer patients (breast, prostate or multiple myeloma) with bone metastases on high&#xD;
             dose antiresorptive treatment (HDAR) for the prevention of bone complications. We will&#xD;
             include all three cancer types (breast cancer, prostate and multiple myeloma) in the&#xD;
             order they are enrolled.&#xD;
&#xD;
          -  The patients should have sufficient compliance, this includes willingness to have the&#xD;
             planned assessments, eg. EORTC QLQ-H&amp;N 35.&#xD;
&#xD;
          -  The patient should have an ECOG score (Eastern Cooperative Oncology Group) â‰¤ 2.&#xD;
&#xD;
          -  Each patient should have a recent (within 3 months) cancer stage and prognosis&#xD;
             assessment by the responsible oncologist before the start of implant treatment.&#xD;
&#xD;
          -  The patient should have an expected life span at enrollment of at least 2 years.&#xD;
&#xD;
          -  The local bone quality and quantity should be sufficient for implant insertion without&#xD;
             bone augmentation and is classified according to the classification by Cawood &amp; Howell&#xD;
             1988.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tobacco smoking&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Poor oral hygiene&#xD;
&#xD;
          -  Poor general condition: ECOG score 3 or 4.&#xD;
&#xD;
          -  Poor prognosis: Expected survival &lt;2 year is an exclusion cause.&#xD;
&#xD;
          -  Cancer assessment is defined by the oncologist.&#xD;
&#xD;
          -  Presence of metastases of the liver brain.&#xD;
&#xD;
          -  Poor local jaw bone quality acc. to Cawood classification stage 3 or 4.&#xD;
&#xD;
          -  Unwillingness to comply with the planned assessments and recordings&#xD;
&#xD;
          -  The patient must not be enrolled in the Amgen supported study: ONJ Registry Study,&#xD;
             Protocol 2010 1102&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanne Werner Moeller Andersen, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital, Maxillofacial surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanne Werner Moeller Andersen, DDS</last_name>
    <phone>60625950</phone>
    <phone_ext>0045</phone_ext>
    <email>sanne@w-madsen.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Kofod, PhD</last_name>
    <phone>35450626</phone>
    <phone_ext>0045</phone_ext>
    <email>thomas.steengaard@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Maxillofacial Department</name>
      <address>
        <city>Copenhagen</city>
        <state>Danmark</state>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanne Werner Moeller Andersen, DDS</last_name>
      <phone>60625950</phone>
      <phone_ext>0045</phone_ext>
      <email>sanne@w-madsen.dk</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Steengaard Kofod, PhD</last_name>
      <phone>35450626</phone>
      <phone_ext>0045</phone_ext>
      <email>thomas.steengaard@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital at Herlev</investigator_affiliation>
    <investigator_full_name>Sanne Werner Moeller Andersen</investigator_full_name>
    <investigator_title>Resident in Oral and Maxillofacial Surgery</investigator_title>
  </responsible_party>
  <keyword>Dental implants</keyword>
  <keyword>High dose antiresorptive medication</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Denosumab</keyword>
  <keyword>Bisphosphonate</keyword>
  <keyword>Oral rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Loss</mesh_term>
    <mesh_term>Anodontia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

